Currently, medicine is, to a large degree, a “one size fits all” proposition. Doctors watch for adverse effects and check personal and family histories. Medical technologies, however, are designed for the general population, not individuals. That’s going to change.

Moreover, there will be huge profit opportunities, in many enabling technologies, for those who invest accordingly. And today I’m going to tell you about a company that will hand you your best chance to make a transformational fortune.

We know that many current treatments work on some people, yet not others. Some drugs are safe for many people, but have dangerous side effects for others. This is because all of us have individual differences in our genetic code based on heredity and environment. Even slight differences can lead to very different reactions to medications.

This has created serious regulatory problems. Drugs are denied regulatory approval not because they do not work, but because some

Lifespan Inc. (Pink Sheets:LSPN) (lifespaninc.com) is excited to announce that Dr. Karim Quyami MD PhD has agreed to lead the Company’s medical and technical advisory team. Dr. Quyami will immediately assume the role of Chief Scientist on the Company’s Medical Advisory Board.

Dr. Quyami is currently the Director of Centre of Excellence for Surgical Education and Innovation (CESEI www.cesei.org). CESEI is a unique world class technology driven facility devoted to redesigning and rethinking the current practice of medicine.

Dr. Quyami is also Director of Research, University of BC Divisions of Cardiovascular and Thoracic Surgery and a Professor in the Department of Surgery. Dr. Quyami is also the primary developer of several fundamental patents in the remote integrated healthcare management arena which could add considerably to the robustness of Lifespan’s medical delivery model.

Dr. Quyami’s primary objectives with Lifespan will be to apply the knowledge and insights gained